cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Akero Therapeutics Inc
11 own
8 watching
Current Price
$18.93
$-1.33
(-6.56%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,348.62M
52-Week High
52-Week High
58.38000
52-Week Low
52-Week Low
11.25000
Average Volume
Average Volume
0.83M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,348.62M
icon52-Week High58.38000
icon52-Week Low11.25000
iconAverage Volume0.83M
iconDividend Yield--
iconP/E Ratio--
What does the Akero Therapeutics Inc do?
Akero Therapeutics, Inc. are a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Their initial focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. Their lead product candidate, AKR-001, which they are developing as a potential treatment for patients with NASH, is an analog of fibroblast growth factor 21, or FGF21. FGF21 is an endogenously-expressed hormone that regulates metabolism of lipids, carbohydrates and proteins throughout the body. FGF21 also plays a critical role in protecting many types of cells from various forms of stress. FGF21 agonists have shown evidence of therapeutic benefit in clinical trials of patients with NASH, many of whom are dyslipidemic and insulin resistant. In previous clinical trials in patients with type 2 diabetes, or T2D, administration of AKR-001 was associated with a substantial improvement in lipid metabolism and insulin sensitivity. They believe these data demonstrate AKR-001's potential to serve as a cornerstone for the treatment of NASH. They plan to initiate a Phase 2a clinical trial for AKR-001 in NASH patients with fibrosis in the middle of 2019. Akero Therapeutics, Inc. were incorporated in January 2017 under the laws of the State of Delaware under the name Pippin Pharmaceuticals, Inc. On May 16, 2018, they changed their name to Akero Therapeutics, Inc. Their principal executive offices are located at 170Harbor Way, 3rd Floor, South San Francisco, CA 94080.
Read More
How much money does Akero Therapeutics Inc make?
News & Events about Akero Therapeutics Inc.
Globe Newswire
10 months ago
Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responsesSOUTH SAN FRANCISCO, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing ...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as ...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the ...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the...
Frequently Asked Questions
Frequently Asked Questions
What is Akero Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Akero Therapeutics Inc shares?
plus_minus_icon
How can I buy Akero Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Akero Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Akero Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Akero Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Akero Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Akero Therapeutics Inc?
plus_minus_icon
What percentage is Akero Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Akero Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$18.93
$-1.33
(-6.56%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$13.96
$-0.13 (-0.92 %)
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
$17.61
$-0.25 (-1.40 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$14.73
$-0.70 (-4.54 %)
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
$24.49
$0.47 (1.96 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$13.96
$-0.13 (-0.92 %)
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
$17.61
$-0.25 (-1.40 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$14.73
$-0.70 (-4.54 %)
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
$24.49
$0.47 (1.96 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00